author-photo

Ali R. Jazirehi

University of California, Los Angeles

70

Papers

2426

Citations

Citation Trend

Filter By

Papers (45) Sort By

Journal Conference Others

CD19-redirected chimeric antigen receptor (CD19 CAR) T cell in the clinical treatment of human non-Hodgkinâs lymphoma and acutelymphoblastic leukemia

2019
Show All
- Source
- Cite
- Save
Citations (0)
Rescue of cell cycle progression in BRAFV600E inhibitor–resistant human melanoma by a chromatin modifier

2017 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (5)
Abstract 1969: Regulation of cell cycle progression in BRAFV600E inhibitor-resistant human melanoma by histone deacetylase inhibitor

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Sensitization of BRAFi- and immune- dual resistant melanomas to immune effector cells through HDACi-mediated regulation of apoptotic machinery (TUM7P.940)

2014 Journal of Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.

2014
Show All
- Source
- Cite
- Save
Citations (25)
Epigenomics and targeted therapy in cancer

2014 Epigenomics
- Ramin Nazarian
- Ali R. Jazirehi
Show All
- Source
- Cite
- Save
Citations (2)
This information is current as TRAIL-Enhanced Apoptosis in Cancer Cells Inhibitor NPI-0052 Contributes to its Expression by the Novel Proteasome Repressor Activity of DR5 Transcription and Inhibition of Yin Yang 1-Dependent

2013
Show All
- Source
- Cite
- Save
Citations (2)
Circumvention of drug-resistance via decitabine-mediated DNMT1 depletion.

2013 Epigenomics
- Antoni X. Torres-Collado
- Ali R. Jazirehi
Show All
- Source
- Cite
- Save
Citations (0)
Epigenetic biomarker of metastatic melanoma.

2013 Epigenomics
- Antoni X. Torres-Collado
- Ali R. Jazirehi
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B292: HDACi immunosensitizes CTL-resistant human melanomas to adoptive cell transfer (ACT) by modulating TRAIL/DR5apoptotic pathway.

2013 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)